Conservative management of acute coronary syndrome: Cheaper and better for you?

Circulation

Volumn 105, Issue 6, 2002, Pages 666-668

  Mark, Daniel B ^a   Lee, Thomas H ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Coronary disease; Cost effectiveness; Editorials; Outcomes

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

CLINICAL TRIAL; CONSERVATIVE TREATMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; EDITORIAL; EXERCISE TEST; FOLLOW UP; HEALTH CARE COST; HEALTH CARE QUALITY; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0037065849     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/circ.105.6.666     Document Type: Editorial

References (14)

1. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC, II prospective randomised multicentre study
2. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial Thrombolysis in Myocardial Ischemia
3. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy: Veterans Affiars Non-Q-Wave Infarction Strategies in Hospital (VANQWlSH)
4. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
5. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)
6. Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: Results of a randomized trial
7. Economics of the TACTICS-TIMI 18 trial
8. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
9. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
10. Efficacy, and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
11. Economics and cardiovascular disease
12. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines), executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty)
13. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men?
14. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy